Palifermin

DB00039

biotech approved

Deskripsi

Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli.

Palifermin was granted FDA approval on 15 December 2004.L17933

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Elimination half-life: 4.5 hours (range: 3.3-5.7 hours)
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

131 Data
Ardeparin The serum concentration of Palifermin can be increased when it is combined with Ardeparin.
Heparin The serum concentration of Palifermin can be increased when it is combined with Heparin.
Enoxaparin The serum concentration of Palifermin can be increased when it is combined with Enoxaparin.
Sulodexide The serum concentration of Palifermin can be increased when it is combined with Sulodexide.
Semuloparin The serum concentration of Palifermin can be increased when it is combined with Semuloparin.
Danaparoid The serum concentration of Palifermin can be increased when it is combined with Danaparoid.
Dalteparin The serum concentration of Palifermin can be increased when it is combined with Dalteparin.
Tinzaparin The serum concentration of Palifermin can be increased when it is combined with Tinzaparin.
Nadroparin The serum concentration of Palifermin can be increased when it is combined with Nadroparin.
Bemiparin The serum concentration of Palifermin can be increased when it is combined with Bemiparin.
Parnaparin The serum concentration of Palifermin can be increased when it is combined with Parnaparin.
Reviparin The serum concentration of Palifermin can be increased when it is combined with Reviparin.
Peginterferon alfa-2a The therapeutic efficacy of Palifermin can be decreased when used in combination with Peginterferon alfa-2a.
Interferon alfa-n1 The therapeutic efficacy of Palifermin can be decreased when used in combination with Interferon alfa-n1.
Interferon alfa-n3 The therapeutic efficacy of Palifermin can be decreased when used in combination with Interferon alfa-n3.
Peginterferon alfa-2b The therapeutic efficacy of Palifermin can be decreased when used in combination with Peginterferon alfa-2b.
Interferon gamma-1b The therapeutic efficacy of Palifermin can be decreased when used in combination with Interferon gamma-1b.
Interferon alfa-2a The therapeutic efficacy of Palifermin can be decreased when used in combination with Interferon alfa-2a.
Aldesleukin The therapeutic efficacy of Palifermin can be decreased when used in combination with Aldesleukin.
Gemtuzumab ozogamicin The therapeutic efficacy of Palifermin can be decreased when used in combination with Gemtuzumab ozogamicin.
Interferon beta-1b The therapeutic efficacy of Palifermin can be decreased when used in combination with Interferon beta-1b.
Interferon alfacon-1 The therapeutic efficacy of Palifermin can be decreased when used in combination with Interferon alfacon-1.
Rituximab The therapeutic efficacy of Palifermin can be decreased when used in combination with Rituximab.
Ibritumomab tiuxetan The therapeutic efficacy of Palifermin can be decreased when used in combination with Ibritumomab tiuxetan.
Tositumomab The therapeutic efficacy of Palifermin can be decreased when used in combination with Tositumomab.
Alemtuzumab The therapeutic efficacy of Palifermin can be decreased when used in combination with Alemtuzumab.
Interferon alfa-2b The therapeutic efficacy of Palifermin can be decreased when used in combination with Interferon alfa-2b.
Phenylalanine The therapeutic efficacy of Palifermin can be decreased when used in combination with Phenylalanine.
Bortezomib The therapeutic efficacy of Palifermin can be decreased when used in combination with Bortezomib.
Cladribine The therapeutic efficacy of Palifermin can be decreased when used in combination with Cladribine.
Carmustine The therapeutic efficacy of Palifermin can be decreased when used in combination with Carmustine.
Amsacrine The therapeutic efficacy of Palifermin can be decreased when used in combination with Amsacrine.
Chlorambucil The therapeutic efficacy of Palifermin can be decreased when used in combination with Chlorambucil.
Raltitrexed The therapeutic efficacy of Palifermin can be decreased when used in combination with Raltitrexed.
Mitomycin The therapeutic efficacy of Palifermin can be decreased when used in combination with Mitomycin.
Bexarotene The therapeutic efficacy of Palifermin can be decreased when used in combination with Bexarotene.
Vindesine The therapeutic efficacy of Palifermin can be decreased when used in combination with Vindesine.
Floxuridine The therapeutic efficacy of Palifermin can be decreased when used in combination with Floxuridine.
Indomethacin The therapeutic efficacy of Palifermin can be decreased when used in combination with Indomethacin.
Tioguanine The therapeutic efficacy of Palifermin can be decreased when used in combination with Tioguanine.
Vinorelbine The therapeutic efficacy of Palifermin can be decreased when used in combination with Vinorelbine.
Dexrazoxane The therapeutic efficacy of Palifermin can be decreased when used in combination with Dexrazoxane.
Sorafenib The therapeutic efficacy of Palifermin can be decreased when used in combination with Sorafenib.
Streptozocin The therapeutic efficacy of Palifermin can be decreased when used in combination with Streptozocin.
Gemcitabine The therapeutic efficacy of Palifermin can be decreased when used in combination with Gemcitabine.
Teniposide The therapeutic efficacy of Palifermin can be decreased when used in combination with Teniposide.
Epirubicin The therapeutic efficacy of Palifermin can be decreased when used in combination with Epirubicin.
Chloramphenicol The therapeutic efficacy of Palifermin can be decreased when used in combination with Chloramphenicol.
Lenalidomide The therapeutic efficacy of Palifermin can be decreased when used in combination with Lenalidomide.
Altretamine The therapeutic efficacy of Palifermin can be decreased when used in combination with Altretamine.
Zidovudine The therapeutic efficacy of Palifermin can be decreased when used in combination with Zidovudine.
Cisplatin The therapeutic efficacy of Palifermin can be decreased when used in combination with Cisplatin.
Oxaliplatin The therapeutic efficacy of Palifermin can be decreased when used in combination with Oxaliplatin.
Cyclophosphamide The therapeutic efficacy of Palifermin can be decreased when used in combination with Cyclophosphamide.
Fluorouracil The therapeutic efficacy of Palifermin can be decreased when used in combination with Fluorouracil.
Propylthiouracil The therapeutic efficacy of Palifermin can be decreased when used in combination with Propylthiouracil.
Pentostatin The therapeutic efficacy of Palifermin can be decreased when used in combination with Pentostatin.
Methotrexate The therapeutic efficacy of Palifermin can be decreased when used in combination with Methotrexate.
Carbamazepine The therapeutic efficacy of Palifermin can be decreased when used in combination with Carbamazepine.
Vinblastine The therapeutic efficacy of Palifermin can be decreased when used in combination with Vinblastine.
Linezolid The therapeutic efficacy of Palifermin can be decreased when used in combination with Linezolid.
Imatinib The therapeutic efficacy of Palifermin can be decreased when used in combination with Imatinib.
Clofarabine The therapeutic efficacy of Palifermin can be decreased when used in combination with Clofarabine.
Pemetrexed The therapeutic efficacy of Palifermin can be decreased when used in combination with Pemetrexed.
Daunorubicin The therapeutic efficacy of Palifermin can be decreased when used in combination with Daunorubicin.
Irinotecan The therapeutic efficacy of Palifermin can be decreased when used in combination with Irinotecan.
Methimazole The therapeutic efficacy of Palifermin can be decreased when used in combination with Methimazole.
Etoposide The therapeutic efficacy of Palifermin can be decreased when used in combination with Etoposide.
Dacarbazine The therapeutic efficacy of Palifermin can be decreased when used in combination with Dacarbazine.
Temozolomide The therapeutic efficacy of Palifermin can be decreased when used in combination with Temozolomide.
Penicillamine The therapeutic efficacy of Palifermin can be decreased when used in combination with Penicillamine.
Tacrolimus The therapeutic efficacy of Palifermin can be decreased when used in combination with Tacrolimus.
Sirolimus The therapeutic efficacy of Palifermin can be decreased when used in combination with Sirolimus.
Mechlorethamine The therapeutic efficacy of Palifermin can be decreased when used in combination with Mechlorethamine.
Azacitidine The therapeutic efficacy of Palifermin can be decreased when used in combination with Azacitidine.
Carboplatin The therapeutic efficacy of Palifermin can be decreased when used in combination with Carboplatin.
Dactinomycin The therapeutic efficacy of Palifermin can be decreased when used in combination with Dactinomycin.
Cytarabine The therapeutic efficacy of Palifermin can be decreased when used in combination with Cytarabine.
Doxorubicin The therapeutic efficacy of Palifermin can be decreased when used in combination with Doxorubicin.
Hydroxyurea The therapeutic efficacy of Palifermin can be decreased when used in combination with Hydroxyurea.
Busulfan The therapeutic efficacy of Palifermin can be decreased when used in combination with Busulfan.
Topotecan The therapeutic efficacy of Palifermin can be decreased when used in combination with Topotecan.
Mercaptopurine The therapeutic efficacy of Palifermin can be decreased when used in combination with Mercaptopurine.
Thalidomide The therapeutic efficacy of Palifermin can be decreased when used in combination with Thalidomide.
Melphalan The therapeutic efficacy of Palifermin can be decreased when used in combination with Melphalan.
Fludarabine The therapeutic efficacy of Palifermin can be decreased when used in combination with Fludarabine.
Flucytosine The therapeutic efficacy of Palifermin can be decreased when used in combination with Flucytosine.
Capecitabine The therapeutic efficacy of Palifermin can be decreased when used in combination with Capecitabine.
Procarbazine The therapeutic efficacy of Palifermin can be decreased when used in combination with Procarbazine.
Arsenic trioxide The therapeutic efficacy of Palifermin can be decreased when used in combination with Arsenic trioxide.
Idarubicin The therapeutic efficacy of Palifermin can be decreased when used in combination with Idarubicin.
Ifosfamide The therapeutic efficacy of Palifermin can be decreased when used in combination with Ifosfamide.
Mitoxantrone The therapeutic efficacy of Palifermin can be decreased when used in combination with Mitoxantrone.
Lomustine The therapeutic efficacy of Palifermin can be decreased when used in combination with Lomustine.
Paclitaxel The therapeutic efficacy of Palifermin can be decreased when used in combination with Paclitaxel.
Docetaxel The therapeutic efficacy of Palifermin can be decreased when used in combination with Docetaxel.
Dasatinib The therapeutic efficacy of Palifermin can be decreased when used in combination with Dasatinib.
Decitabine The therapeutic efficacy of Palifermin can be decreased when used in combination with Decitabine.
Nelarabine The therapeutic efficacy of Palifermin can be decreased when used in combination with Nelarabine.
Everolimus The therapeutic efficacy of Palifermin can be decreased when used in combination with Everolimus.

Target Protein

Fibroblast growth factor receptor 2 FGFR2
Fibroblast growth factor receptor 1 FGFR1
Basement membrane-specific heparan sulfate proteoglycan core protein HSPG2

Referensi & Sumber

Artikel (PubMed)
  • PMID: 19707400
    Barasch A, Epstein J, Tilashalski K: Palifermin for management of treatment-induced oral mucositis in cancer patients. Biologics. 2009;3:111-6. doi: 10.2147/btt.2009.2871. Epub 2009 Jul 13.
  • PMID: 8663044
    Ornitz DM, Xu J, Colvin JS, McEwen DG, MacArthur CA, Coulier F, Gao G, Goldfarb M: Receptor specificity of the fibroblast growth factor family. J Biol Chem. 1996 Jun 21;271(25):15292-7.
  • PMID: 11422746
    Cancilla B, Davies A, Cauchi JA, Risbridger GP, Bertram JF: Fibroblast growth factor receptors and their ligands in the adult rat kidney. Kidney Int. 2001 Jul;60(1):147-55.

Contoh Produk & Brand

Produk: 4 • International brands: 0
Produk
  • Kepivance
    Injection • 6.25 mg/1mL • Intravenous • US • Approved
  • Kepivance
    Injection, powder, lyophilized, for solution • 6.25 mg/1.2mL • Intravenous • US • Approved
  • Kepivance
    Powder, for solution • 6.25 mg / vial • Intravenous • Canada • Approved
  • Kepivance
    Injection, powder, lyophilized, for solution • 5.16 mg/1.2mL • Intravenous • US • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul